Metabolic Profiling of the EmDia Cohort by LC-MS Reveals Empagliflozin-Intake Associated Regulation of 1,5-anhydroglucitol and Urate.

ABSTRACT: The EmDia trial, designed to study the effects of the sodium glucose cotransporter-2 (SGLT2) inhibitor empagliflozin on cardiovascular comorbidities in type 2 diabetes mellitus (T2DM) patients, has been investigated for short-term metabolic alterations by a limited set of clinical assays. To expand on this data, we report on the development of a liquid chromatography-mass spectrometry (LC-MS)-based metabolomics approach employing an optimized metabolite separation by pentafluorophenyl chromatography. High-confidence metabolite annotation based on reference standards allows for fast and robust metabolic characterization of large plasma cohorts due to scalability. Applied to EmDia, we show the high predictive power of our methodology for several clinical parameters, including a near-perfect

SUBMITTER: Schmitt F 

PROVIDER: S-EPMC12809005 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature